|
π
|
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
11 auth.
T. King,
K. Brown,
G. Raghu,
R. D. du Bois,
D. Lynch,
F. Martinez,
...
D. Valeyre,
I. Leconte,
A. Morganti,
S. Roux,
J. Behr
|
9 |
2011 |
9
π
|
|
π
|
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
10 auth.
C. R. Rocha Lima,
M. Green,
R. Rotche,
W. Miller,
G. Jeffrey,
L. Cisar,
...
A. Morganti,
Nicoletta Orlando,
G. Gruia,
L. Miller
|
9 |
2004 |
9
π
|
|
π
|
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
14 auth.
X. JaΓ―s,
A. D'Armini,
P. Jansa,
A. Torbicki,
M. Delcroix,
H. Ghofrani,
M. Hoeper,
I. Lang,
E. Mayer,
J. Pepke-Zaba,
...
L. Perchenet,
A. Morganti,
G. Simonneau,
L. Rubin
|
9 |
2008 |
9
π
|
|
π¬
|
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
G. Raghu,
Rachel Million-Rousseau,
A. Morganti,
LoΡc Perchenet,
J. Behr
|
8 |
2013 |
8
π¬
|
|
π
|
Effects of long-term bosentan in children with pulmonary arterial hypertension.
10 auth.
E. Rosenzweig,
D. Ivy,
A. Widlitz,
A. Doran,
L. Claussen,
D. Yung,
...
S. Abman,
A. Morganti,
Ngoc-Yen T Nguyen,
R. Barst
|
8 |
2005 |
8
π
|
|
π
|
Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study
14 auth.
M. Beghetti,
S. Haworth,
D. Bonnet,
R. Barst,
P. Acar,
A. Fraisse,
D. Ivy,
X. Jais,
I. Schulze-Neick,
N. Galiè,
...
A. Morganti,
J. Dingemanse,
Andjela Kusic-Pajic,
R. Berger
|
6 |
2009 |
6
π
|
|
π
|
MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis
8 auth.
Y. Bauer,
E. White,
Simon de Bernard,
P. Cornelisse,
I. Leconte,
A. Morganti,
...
S. Roux,
O. Nayler
|
6 |
2017 |
6
π
|
|
π
|
A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma
13 auth.
R. Kefford,
J. Beith,
G. Hazel,
M. Millward,
J. Trotter,
D. Wyld,
Rada Kusic,
R. Shreeniwas,
A. Morganti,
A. Ballmer,
...
E. Segal,
O. Nayler,
M. Clozel
|
5 |
2005 |
5
π
|
|
π¬
|
A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy
R. Kefford,
P. Clingan,
B. Brady,
A. Ballmer,
A. Morganti,
P. Hersey
|
5 |
2010 |
5
π¬
|
|
π
|
Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis open label extension to a double-blind trial
10 auth.
C. Black,
C. Denton,
D. Furst,
M. Matucci-Cerinic,
Mayes,
J. Popes,
...
Seibold,
A. Morganti,
Fabrice Kramer,
J. Korn
|
5 |
2006 |
5
π
|
|
π¬
|
Hunter syndrome (Mucopolysaccharidosis type II), severe phenotype: long term follow-up on patients undergone to hematopoietic stem cell transplantation.
R. Annibali,
L. Caponi,
A. Morganti,
M. Manna,
O. Gabrielli,
A. Ficcadenti
|
4 |
2013 |
4
π¬
|
